You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-H Colorectal Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

MSI-H Colorectal Cancer Trial in Pittsburgh (Regorafenib, Pembrolizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Aug 17, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • (no location specified)
Apr 23, 2023

MSI-H Colorectal Cancer Trial (colorectal resection)

Completed
  • MSI-H Colorectal Cancer
  • colorectal resection
  • (no location specified)
May 22, 2023

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H

Recruiting
  • Colorectal Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Oct 18, 2023

    Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

    Not yet recruiting
    • Multiple Cancer
    • Colorectal Cancer
    • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
    • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
    • (no location specified)
    Aug 20, 2023

    dMMR Colorectal Cancer Trial in Beijing (Cadonilimab)

    Recruiting
    • dMMR Colorectal Cancer
    • Beijing, Beijing, China
      National Cancer Center/Cancer Hospital, Chinese Academy of Medic
    Apr 13, 2023

    Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)

    Not yet recruiting
    • Gastric
    • Colorectal Adenocarcinoma
    • Shenyang, Liaoning, China
      Liaoning Cancer Hospital & Institute
    Nov 1, 2023

    Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

    Recruiting
    • Colorectal Carcinoma
    • Guangzhou, China
      Sun Yat-sen University
    Dec 29, 2022

    Immunotherapy in MSI-H Metastatic Colorectal Cancer

    Recruiting
    • Colorectal Cancer
    • Carpi, Modena, Italy
      Ospedale Ramazzini
    Sep 5, 2022

    DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer Trial in Guangzhou (drug, radiation,

    Recruiting
    • DMMR Colorectal Cancer
    • +2 more
    • PD-1 Antibody
    • +4 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Sep 22, 2021

    Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

    Active, not recruiting
    • Colorectal Cancer
    • IBI310 (anti-CTLA-4 antibody)
    • Sintilimab(anti-PD-1 antibody)
    • Beijing, China
      Beijing cancer hospital
    Sep 15, 2022

    Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

    Not yet recruiting
    • Colorectal Cancer Stage IV
    • +2 more
    • (no location specified)
    Jun 19, 2022

    MSI-H Advanced Colorectal Cancer Trial in Tianjin (Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen)

    Recruiting
    • MSI-H Advanced Colorectal Cancer
    • Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Institute & Hospital
    Sep 3, 2021

    Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • HX008
    • Investigator's Choice Chemotherapy
    • Hefei, Anhui, China
    • +9 more
    Dec 8, 2022

    Breast Cancer, Melanoma, Non Small Cell Lung Cancer Trial in Brussel (Checkpoint Blockade, Immune)

    Recruiting
    • Breast Cancer
    • +12 more
    • Checkpoint Blockade, Immune
    • Brussel, Anderlecht, Belgium
      Institut Jules Bordet
    Jul 1, 2022

    Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite

    Recruiting
    • Advanced Microsatellite Stable Colorectal Carcinoma
    • +5 more
    • Atlanta, Georgia
    • +2 more
    Oct 29, 2021

    Colorectal Cancer Trial in China (Tislelizumab)

    Recruiting
    • Colorectal Cancer
    • Bengbu, Anhui, China
    • +7 more
    Sep 13, 2022

    Colorectal Cancer Trial in Essen (Atezolizumab)

    Recruiting
    • Colorectal Cancer
    • Essen, Germany
      Westdeutsches Tumorzentrum
    Feb 14, 2022

    Advanced Cancer, Advanced Solid Tumor, Tumor Malignant Trial in United Kingdom (Fosifloxuridine Nafalbenamide, Leucovorin,

    Not yet recruiting
    • Advanced Cancer
    • +16 more
    • Fosifloxuridine Nafalbenamide
    • +3 more
    • Birmingham, United Kingdom
    • +3 more
    Feb 1, 2023

    Colorectal Carcinoma Trial in Beijing (Toripalimab, Bevacizumab, Irinotecan)

    Recruiting
    • Colorectal Carcinoma
    • Beijing, Beijing, China
      Peking University Cancer Hospital and Institute
    Jul 31, 2021

    Colorectal Tumors Trial in China (Pembrolizumab, Oxaliplatin, Leucovorin)

    Recruiting
    • Colorectal Neoplasms
    • Pembrolizumab
    • +6 more
    • Beijing, Beijing, China
    • +21 more
    Jan 25, 2023

    Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

    Recruiting
    • Breast Cancer
    • +15 more
    • ATRC-101
    • +2 more
    • Phoenix, Arizona
    • +10 more
    Sep 28, 2022